Hormone replacement therapy after breast cancer: attitudes of women eligible in a randomized trial

被引:2
作者
Wallberg, B. [1 ,2 ,3 ]
von Schoultz, E.
Bolund, C. [2 ,3 ]
Bergh, J. [2 ,3 ]
Wilking, N.
机构
[1] Karolinska Inst, Radiumhemmet, Dept Oncol Pathol, S-17176 Stockholm, Sweden
[2] Canc Ctr Karolinska, Dept Oncol Pathol, Stockholm, Sweden
[3] Karolinska Univ Hosp, S-17176 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
BREAST CANCER; HORMONE REPLACEMENT THERAPY; RANDOMIZED STUDY; ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; HEALTHY POSTMENOPAUSAL WOMEN; INFORMATION NEEDS; CLINICAL-TRIALS; FOLLOW-UP; RISK; PARTICIPATION; PREFERENCES; CARCINOMA;
D O I
10.3109/13697130902912597
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives To investigate the attitudes of breast cancer patients who accepted or declined participation in a randomized trial with hormone replacement therapy that might increase their risk of recurrence (the Stockholm trial). Methods A total of 115 patients free from breast cancer recurrence were interviewed; 57 were participants and 58 were non-participants in the Stockholm trial. Patients answered five questionnaires regarding information needs (two), attitudes to participation in trials (two) and patient role in treatment decisions (one). Results Participants in the Stockholm trial had a lower risk of breast cancer recurrence (measured by node-positive disease and tumor size) and were older than non-participants. Their information needs were the same. Participants in the trial were more prepared to accept uncertainty, to have an altruistic attitude, to accept risks including an increased risk of recurrence of breast cancer, if their quality of life or general health was improved. Most patients preferred a collaborative role in relation to their physician but participants often wanted more influence than they had in treatment decisions. Conclusion A patient's decision to accept or decline participation in the Stockholm trial was influenced by her objective risk of breast cancer recurrence and reflected her attitude to risk, uncertainty and preference to be active in treatment decisions.
引用
收藏
页码:478 / 489
页数:12
相关论文
共 34 条
[1]  
[Anonymous], CANC NURS
[2]  
Beral Valerie, 2003, Lancet, V362, P419
[3]   THE RISK OF BREAST-CANCER AFTER ESTROGEN AND ESTROGEN PROGESTIN REPLACEMENT [J].
BERGKVIST, L ;
ADAMI, HO ;
PERSSON, I ;
HOOVER, R ;
SCHAIRER, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (05) :293-297
[4]   ATTITUDES TOWARD CLINICAL-TRIALS AMONG PATIENTS AND THE PUBLIC [J].
CASSILETH, BR ;
LUSK, EJ ;
MILLER, DS ;
HURWITZ, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 248 (08) :968-970
[5]   Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women - The Women's Health Initiative Randomized trial [J].
Chlebowski, RT ;
Hendrix, SL ;
Langer, RD ;
Stefanick, ML ;
Gass, M ;
Lane, D ;
Rodabough, RJ ;
Gilligan, MA ;
Cyr, MG ;
Thomson, CA ;
Khandekar, J ;
Petrovitch, H ;
McTiernan, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (24) :3243-3253
[6]   Information needs and decisional preferences in women with breast cancer [J].
Degner, LF ;
Kristjanson, LJ ;
Bowman, D ;
Sloan, JA ;
Carriere, KC ;
ONeil, J ;
Bilodeau, B ;
Watson, P ;
Mueller, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1485-1492
[7]  
Dew JE, 2002, CLIMACTERIC, V5, P151
[8]   Attitudes towards and participation in randomised clinical trials in oncology: A review of the literature [J].
Ellis, PM .
ANNALS OF ONCOLOGY, 2000, 11 (08) :939-945
[9]   HORMONE REPLACEMENT THERAPY AND THE RISK OF STROKE - FOLLOW-UP OF A POPULATION-BASED COHORT IN SWEDEN [J].
FALKEBORN, M ;
PERSSON, I ;
TERENT, A ;
ADAMI, HO ;
LITHELL, H ;
BERGSTROM, R .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (10) :1201-1209
[10]   THE RISK OF ACUTE MYOCARDIAL-INFARCTION AFTER ESTROGEN AND ESTROGEN PROGESTOGEN REPLACEMENT [J].
FALKEBORN, M ;
PERSSON, I ;
ADAMI, HO ;
BERGSTROM, R ;
EAKER, E ;
LITHELL, H ;
MOHSEN, R ;
NAESSEN, T .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1992, 99 (10) :821-828